NCT02768805 is a Phase 2 clinical trial of 15 µg/strain of Quadrivalent VLP Vaccine in Virus Diseases, sponsored by Medicago.

Who is sponsoring NCT02768805?

NCT02768805 is sponsored by Medicago.

What drugs are being tested in NCT02768805?

Interventions in NCT02768805: 15 µg/strain of Quadrivalent VLP Vaccine, 30 µg/strain of Quadrivalent VLP Vaccine, 15 µg/strain of the licensed quadrivalent vaccine.

What condition does NCT02768805 study?

NCT02768805 studies Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections.

Is NCT02768805 still recruiting?

NCT02768805 is currently completed. Last updated 11 June 2020.

Last reviewed 2020-06-11 · How we verify

NCT02768805

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults

Completed Phase 2 Last updated 11 June 2020

What this trial tests

Phase 2 trial testing 15 µg/strain of Quadrivalent VLP Vaccine in Virus Diseases in 900 participants. Completed in 26 November 2016.

Timeline

2 March 2016

Primary endpoint
17 May 2016

26 November 2016

Quick facts

Lead sponsor	Medicago
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	900
Start date	2 March 2016
Primary completion	17 May 2016
Estimated completion	26 November 2016
Sites	9 locations across Canada, United States

Drugs / interventions tested

15 µg/strain of Quadrivalent VLP Vaccine — full drug profile →
30 µg/strain of Quadrivalent VLP Vaccine — full drug profile →
15 µg/strain of the licensed quadrivalent vaccine — full drug profile →

Conditions studied

Virus Diseases — all drugs for Virus Diseases →
RNA Virus Infections — all drugs for RNA Virus Infections →
Respiratory Tract Diseases — all drugs for Respiratory Tract Diseases →
Respiratory Tract Infections — all drugs for Respiratory Tract Infections →

Sponsor

Medicago — full company profile →

Who can join

Adults 18 to 64, any sex, with Virus Diseases or RNA Virus Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies. The study is being conducted to demonstrate that the immunogenicity profile of the Quadrivalent VLP Vaccine meets the US Center for Biologics Evaluation and Research (CBER) licensure criteria. The study will also help to define the optimal dose, establish potential competitive advantages, and support the design of future studies.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Virus-like particle vaccinology, from bench to bedside.
Mohsen MO, Bachmann MF. · · 2022 · cited 181× · PMID 35962190 · DOI 10.1038/s41423-022-00897-8
Virus-like particle vaccines: immunology and formulation for clinical translation.
Donaldson B, Lateef Z, Walker GF, Young SL, et al · · 2018 · cited 108× · PMID 30173619 · DOI 10.1080/14760584.2018.1516552
Platforms, advances, and technical challenges in virus-like particles-based vaccines.
Gupta R, Arora K, Roy SS, Joseph A, et al · · 2023 · cited 80× · PMID 36845125 · DOI 10.3389/fimmu.2023.1123805
Plant Viruses and Bacteriophage-Based Reagents for Diagnosis and Therapy.
Shukla S, Hu H, Cai H, Chan SK, et al · · 2020 · cited 27× · PMID 32991265 · DOI 10.1146/annurev-virology-010720-052252

Verify or expand the search:

Other recruiting trials for Virus Diseases

Currently open trials in the same condition.

NCT05797246 — Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) · Phase 2 · active not recruiting
NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting

Other Medicago trials

Trials by the same sponsor.

NCT05040789 — Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine · Phase 3 · withdrawn
NCT05065619 — Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19） · Phase 1, PHASE2 · terminated
NCT04636697 — Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults · Phase 2, PHASE3 · active not recruiting
NCT04622592 — Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and · Phase 1, PHASE2 · completed
NCT04450004 — Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years. · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02768805 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medicago
Last refreshed: 11 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02768805.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing